Dohmen Luuk C T, Navas Adriana, Vargas Deninson Alejandro, Gregory David J, Kip Anke, Dorlo Thomas P C, Gomez Maria Adelaida
From the Centro Internacional de Entrenamiento e Investigaciones Médicas, Cra. 125 # 19-225 Cali, Colombia, the Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3508 TB Utrecht, The Netherlands.
From the Centro Internacional de Entrenamiento e Investigaciones Médicas, Cra. 125 # 19-225 Cali, Colombia.
J Biol Chem. 2016 Apr 29;291(18):9638-47. doi: 10.1074/jbc.M115.688168. Epub 2016 Feb 22.
Within its mammalian host, Leishmania resides and replicates as an intracellular parasite. The direct activity of antileishmanials must therefore depend on intracellular drug transport, metabolism, and accumulation within the host cell. In this study, we explored the role of human macrophage transporters in the intracellular accumulation and antileishmanial activity of miltefosine (MLF), the only oral drug available for the treatment of visceral and cutaneous leishmaniasis (CL). Membrane transporter gene expression in primary human macrophages infected in vitro with Leishmania Viannia panamensis and exposed to MLF showed modulation of ABC and solute liquid carrier transporters gene transcripts. Among these, ABCA3, a lipid transporter, was significantly induced after exposure to MLF, and this induction was confirmed in primary macrophages from CL patients. Functional validation of MLF as a substrate for ABCA3 was performed by shRNA gene knockdown (KD) in THP-1 monocytes. Intracellular accumulation of radiolabeled MLF was significantly higher in ABCA3(KD) macrophages. ABCA3(KD) resulted in increased cytotoxicity induced by MLF exposure. ABCA3 gene expression inversely correlated with intracellular MLF content in primary macrophages from CL patients. ABCA3(KD) reduced parasite survival during macrophage infection with an L. V. panamensis strain exhibiting low in vitro susceptibility to MLF. Confocal microscopy showed ABCA3 to be located in the cell membrane of resting macrophages and in intracellular compartments in L. V. panamensis-infected cells. These results provide evidence of ABCA3 as an MLF efflux transporter in human macrophages and support its role in the direct antileishmanial effect of this alkylphosphocholine drug.
在其哺乳动物宿主内,利什曼原虫作为细胞内寄生虫生存和繁殖。因此,抗利什曼药物的直接活性必须依赖于细胞内药物转运、代谢以及在宿主细胞内的积累。在本研究中,我们探究了人类巨噬细胞转运蛋白在米替福新(MLF)的细胞内积累及抗利什曼活性中的作用,米替福新是唯一可用于治疗内脏利什曼病和皮肤利什曼病(CL)的口服药物。体外感染巴拿马利什曼原虫并暴露于MLF的原代人类巨噬细胞中,膜转运蛋白基因表达显示ABC转运蛋白和溶质载体转运蛋白基因转录本受到调节。其中,脂质转运蛋白ABCA3在暴露于MLF后显著上调,并且在CL患者的原代巨噬细胞中也得到了证实。通过在THP-1单核细胞中进行shRNA基因敲除(KD),对MLF作为ABCA3底物进行了功能验证。在ABCA3(KD)巨噬细胞中,放射性标记的MLF细胞内积累显著更高。ABCA3(KD)导致MLF暴露诱导的细胞毒性增加。CL患者原代巨噬细胞中ABCA3基因表达与细胞内MLF含量呈负相关。ABCA3(KD)降低了用对MLF体外敏感性较低的巴拿马利什曼原虫菌株感染巨噬细胞期间的寄生虫存活率。共聚焦显微镜显示ABCA3位于静息巨噬细胞的细胞膜以及巴拿马利什曼原虫感染细胞的细胞内区室中。这些结果提供了ABCA3作为人类巨噬细胞中MLF外排转运蛋白的证据,并支持其在这种烷基磷酸胆碱药物的直接抗利什曼作用中的作用。